Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Teva Pharmaceutical Indus (NasdaqNM:TEVA)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs | Insider | Options
Recent Events
July 25Conference call: Teva Pharmaceutical Industries Quarterly
Aug 15Conference call: Teva Pharmaceutical Industries
Upcoming Events
Sep 17Dividend payment of $0.05
Location
5 Basel Street, PO Box 3190
Petach Tikva 49131, Israel
Phone: (212) 510-9286
Fax: (212) 363-3971
Email: ir@teva.co.il
Employees (last reported count): 8,750
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 10%
·Institutional: 48% (54% of float)
(485 institutions)
·Net Inst. Selling: 3.94M shares (+6.82%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Teva Pharmaceutical Industries Ltd. is a fully integrated global pharmaceutical company producing drugs in all major therapeutic categories. In the area of proprietary drugs, Teva has focused on products for central nervous system disorders, primarily the development of Teva's first globally marketed branded drug, Copaxone, a treatment for relapsing-remitting multiple sclerosis. Teva also possesses significant manufacturing operations for active pharmaceutical ingredients (API). Teva Pharmaceuticals USA, Inc., Teva's principal United States subsidiary, is a generic drug company in the United States. Teva manufactures 137 generic products in 210 generic forms, which are distributed and sold in the United States together with 15 additional generic products in 29 dosage forms manufactured by third parties. Teva manufactures over 270 generic products in 600 dosage forms, which are sold primarily in the Netherlands, the United Kingdom and Hungary.
More from Market Guide: Expanded Business Description

Financial Summary
Teva Pharmaceutical Industries Ltd. through its subsidiaries and associated companies develops, distributes, produces and markets all major theraputic drugs. For the six months ended 6/30/01, sales increased 29% to $1 billion. Net income before US GAAP totalled $119.2 million, up from $45.2 million. Revenues reflect the acquisitions of Novopharm and increased sales of new products. Earnings also reflect higher margins due to economies of scale and and lower interest expense.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]

Position
Meir Heth, 68Chairman
Eli Hurvitz, 68Pres, Chief Exec. Officer
Dan Suesskind, 57CFO, Director
Israel Makov, 62COO
Haim Benjamin, 61VP, HR
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:TEVAAs of 31-Aug-2001
Price and Volume
52-Week Low
on 23-Jan-2001
$48.50 
Recent Price$71.10 
52-Week High
on 29-Sep-2000
$78.75 
Beta-0.17 
Daily Volume (3-month avg)1.17M
Daily Volume (10-day avg)1.00M
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+16.6%
52-Week Change
relative to S&P500
+56.4%
Share-Related Items
Market Capitalization$9.10B
Shares Outstanding127.9M
Float115.1M
Dividends & Splits
Annual Dividendnone 
Last Split: 2 for 1 on 23-Feb-2000
Per-Share Data
Book Value (mrq)$9.46 
Earnings (ttm)$1.61 
Earnings (mrq)$0.46 
Sales (ttm)$14.25 
CashN/A 
Valuation Ratios
Price/Book (mrq)7.52 
Price/Earnings (ttm)44.05 
Price/Sales (ttm)4.99 
Income Statements
Sales (ttm)$1.97B
EBITDA (ttm)$321.1M
Income available to common (ttm)$223.8M
Profitability
Profit Margin (ttm)11.4%
Operating Margin (ttm)16.3%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)8.49%
Return on Equity (ttm)19.50%
Financial Strength
Current Ratio (mrq)2.29 
Debt/Equity (mrq)0.44 
Total CashN/A 
Short Interest
As of 8-Aug-2001
Shares Short1.88M
Percent of Float1.6%
Shares Short
(Prior Month)
1.63M
Short Ratio1.22 
Daily Volume1.55M
ADR Information
Shares/ADR1
See Profile Help for a description of each item above;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.